Gladstone in the News
January 10, 2022
ABC News—COVID-19 vaccine maker Moderna recently announced that individuals might need a fourth shot to stay safe in the ongoing pandemic. Gladstone virologist Warner Greene argues that an additional dose of the available vaccine may not be ideal, and that future boosters should be designed to specifically protect against emerging strains of the virus.
Gladstone Experts
COVID-19
Virology
Greene Lab
Gladstone in the News
December 15, 2021
abc7 NEWS—Senior Investigator Leor Weinberger, PhD, and Research Investigator Sonali Chaturvedi, PhD, explain their work on a therapy that sharply reduces viral load in the nose of hamsters after a single administration and could add a promising new tool to the therapeutic arsenal against COVID-19.
Gladstone Experts
COVID-19
Virology
Weinberger Lab
Gladstone in the News
December 14, 2021
San Francisco Business Times—Senior Investigator Leor Weinberger, PhD, pioneered a new class of antivirals called therapeutic interfering particles (TIPs), which were recently shown to be effective against SARS-CoV-2 in animal models. The approach is now being developed by a startup company and will be headed to clinical trials.
Gladstone Experts
COVID-19
Center for Cell Circuitry
Virology
Weinberger Lab
Gladstone in the News
December 14, 2021
San Francisco Chronicle—The omicron variant of SARS-CoV-2 is spreading rapidly, but it may not be a reason for panic. Nadia Roan explains that our immune system’s cellular response to the vaccines should hold up well against the omicron variant. In addition, Warner Greene predicts that if the variant spreads rapidly but causes just mild disease, it might actually help establish immunity globally, protecting people in places where vaccine access has been limited.
Gladstone Experts
COVID-19
Greene Lab
Roan Lab
Gladstone in the News
December 6, 2021
San Francisco Chronicle—The identification of an individual infected with the Omicron variant of SARS-CoV-2 in San Francisco is helping local scientists assess the danger posed by the virus. Melanie Ott, director of the Gladstone Institute of Virology, explains that experiments using virus samples from that individual could help determine how well the available vaccines hold up to Omicron’s mutations.
Gladstone Experts
COVID-19
Virology
Ott Lab
Gladstone in the News
December 1, 2021
San Francisco Chronicle—The emerging Omicron variant of SARS-CoV-2 features several mutations in its spike protein that in theory could make it resistant to current vaccines. But Associate Investigator Nadia Roan, PhD, explains that current vaccines will still protect against Omicron, as they elicit a variety of antibodies and immune T cells that target non-mutated areas of spike.
Gladstone Experts
COVID-19
Virology
Roan Lab
Gladstone in the News
November 26, 2021
ABC News—A new variant of SARS-CoV-2, dubbed Omicron, is causing concern around the world. Gladstone President Deepak Srivastava explains that some of the variant’s 50 mutations may have arisen when an individual who was already immunocompromised became infected with the virus. Senior Investigator Nevan Krogan describes how his group is investigating whether the new mutations will change the ability of the virus to enter cells and cause disease.
Gladstone Experts
COVID-19
Data Science and Biotechnology
Virology
Krogan Lab
Srivastava Lab
Gladstone in the News
November 18, 2021
NIH Director’s Blog—The Delta variant of SARS-CoV-2 is driving the latest surge of COVID-19 cases in the United States. New research from Senior Investigators Jennifer Doudna and Melanie Ott explains how mutations in this variant increase transmissibility.
Gladstone Experts
COVID-19
Virology
Doudna Lab
Ott Lab
Gladstone in the News
November 3, 2021
Scientific American—There is increasing evidence that some people who recover from COVID-19 suffer from lingering heart problems, a phenomenon known as post-COVID-19 cardiac syndrome. Senior Investigator Bruce Conklin explains that it’s important to investigate the long-term consequences of infection, and describes his team’s work showing that infecting heart cells with SARS-CoV-2 can result in dramatic structural damage.
Gladstone Experts
COVID-19
Cardiovascular Disease
Conklin Lab
Gladstone in the News
November 3, 2021
San Francisco Chronicle—Associate Investigator Nadia Roan, PhD, comments on a potentially new type of COVID-19 vaccine that would fight the virus at its points of entry—the nose, throat, or lungs—and may provide even better protection than current shots in the arm.
Gladstone Experts
COVID-19
Virology
Roan Lab
